Table 1.
Laboratory data at the time of administration
| WBC | 7260/μL | IgG | 1215 mg/dL |
| stab | 4% | IgA | 612 mg/dL |
| seg | 60% | IgM | 182 mg/dL |
| lym | 27% | ANA | < 1:40 |
| mono | 8% | anti-DNA-Ab | < 2.0 U/mL |
| eos | 1% | C3 | 97 mg/dL |
| baso | 0% | C4 | 26 mg/dL |
| RBC | 503 × 104/μL | CH50 | 38 U/mL |
| Hb | 14.3 g/dL | MPO-ANCA | < 1.0 U/mL |
| Hct | 42.9% | PR3-ANCA | < 1.0 U/mL |
| Plt | 39.9 × 104/μL | anti-GBM-Ab | < 2.0 U/mL |
| TP | 6.0 g/dL | HBS-Ag | < 0.03 IU/mL |
| Alb | 1.9 g/dL | HBC-Ab | < 1.0 |
| ALT | 16 U/L | HCV-DNA | < 1.0 |
| AST | 8 U/L | HIV-Ag/Ab | < 1.0 |
| LDH | 156 U/L | HHV-8-DNA | < 2.0 × 101 copy |
| CRP | 0.76 mg/dL | ||
| BUN | 6.6 mg/dL | VEGF | 1290 pg/mL |
| Cre | 0.67 mg/dL | IL-6 | 6.7 pg/mL |
| UA | 5.0 mg/dL | ||
| TC | 293 mg/dL | Proteinuria | 7009 mg/day |
| Urinary RBC | 20.0/μL |
ANA antinuclear antibody, Ab antibody, CH50 total complement level, MPO-ANCA myeloperoxidase–antineutrophil cytoplasmic antibody, PR3-ANCA proteinase 3-antineutrophil cytoplasmic antibody, HBS hepatitis B surface, Ag antigen, HBC hepatitis B core, HCV hepatitis C virus, HIV human immunodeficiency virus, HHV-8 human herpesvirus 8, VEGF vascular endothelial growth factor, IL-6 interleukin 6